Modulari-T Bioscience is pioneering advancements in cell therapy through its innovative Modular Actuation Receptor Cells (MARC) technology. This approach leverages the natural architecture of immune receptors to create a more effective immunotherapy for cancer and autoimmune diseases. MARC technology features a modular design that separates targeting and signaling functions, allowing for powerful and precise activation of immune cells. This design minimizes the risk of toxicities commonly associated with traditional therapies, such as CAR-T, by preventing tonic signaling that can lead to cell exhaustion and cytokine release syndrome. The MARC system is engineered to provide a sustained immune response, enhancing the potential for long-term recovery and reducing the likelihood of disease relapse.

Additionally, MARC technology is versatile and compatible with various immune cell types, including T cells, natural killer (NK) cells, macrophages, monocytes, and dendritic cells. It is also compatible with induced pluripotent stem cells (iPSCs), enabling the recreation of a complete immune system capable of generating a comprehensive anti-cancer response. This immune cell-agnostic approach not only enhances the therapeutic potential of cell therapies but also offers a scalable and cost-effective solution for treating complex diseases. By focusing on customized signaling outputs, MARC technology aims to direct specific immune behaviors, ultimately leading to safer and more effective treatments for patients.

Canada

Cell and gene therapy promises to one day cure any pathology; Modulari-T’s MARC Platform produces the tools to fulfill that promise.

Modulari-T Bioscience

Company Details